ASX

SSR Mining Provides an Update on Incident at Çöpler

Retrieved on: 
Saturday, February 17, 2024

SSR Mining Inc. (Nasdaq/TSX: SSRM; ASX: SSR) (“SSR Mining” or the “Company”) today provides an update on ongoing rescue efforts at the Çöpler Mine in Türkiye.

Key Points: 
  • SSR Mining Inc. (Nasdaq/TSX: SSRM; ASX: SSR) (“SSR Mining” or the “Company”) today provides an update on ongoing rescue efforts at the Çöpler Mine in Türkiye.
  • Search and rescue operations to locate nine missing workers following the February 13, 2024 incident at the Çöpler Mine continue and all operations remain suspended.
  • SSR Mining is providing its full cooperation to the regulators on site and providing support to the individuals and their families.
  • SSR Mining will provide a further update on the incident as it becomes aware of more information or during the Company’s full-year 2023 financial results, currently scheduled for Wednesday, February 21, 2024.

Media Alert: BrainChip CEO Talks Successes and Momentum in the Latest Investor Podcast

Retrieved on: 
Thursday, February 15, 2024

In this fourth episode of BrainChip’s Quarterly Investor Podcast, Director of Global Investor Relations Tony Dawe presents these questions to Hehir across a range of topics including successes achieved during the past year, the latest product updates, and other various shareholder interests.

Key Points: 
  • In this fourth episode of BrainChip’s Quarterly Investor Podcast, Director of Global Investor Relations Tony Dawe presents these questions to Hehir across a range of topics including successes achieved during the past year, the latest product updates, and other various shareholder interests.
  • Among the topics covered in this podcast are:
    Achievements made by BrainChip in 2023 and what the company is doing to continue this positive momentum throughout 2024.
  • Emergent themes coming out of CES 2024 and how BrainChip is poised to address them.
  • “The BrainChip Investor Podcast is an ideal venue for me to communicate the company’s successes, milestones and plans based on input direct from our investment community.

Piedmont Lithium to Release Fourth-Quarter & Full-Year 2023 Results on February 22, 2024

Retrieved on: 
Thursday, February 15, 2024

Piedmont Lithium (“Piedmont” or the “Company”) (Nasdaq: PLL; ASX: PLL), a leading global supplier of lithium resources critical to the U.S. electric vehicle supply chain, today announced that it will release its fourth-quarter and full-year 2023 earnings following the Nasdaq close on Thursday, February 22, 2024.

Key Points: 
  • Piedmont Lithium (“Piedmont” or the “Company”) (Nasdaq: PLL; ASX: PLL), a leading global supplier of lithium resources critical to the U.S. electric vehicle supply chain, today announced that it will release its fourth-quarter and full-year 2023 earnings following the Nasdaq close on Thursday, February 22, 2024.
  • The Company will hold a conference call to discuss fourth-quarter and full-year 2023 results on Thursday, February 22, 2024, at 4:30 p.m. Eastern Time (U.S. and Canada).
  • Our goal is to become one of the largest lithium hydroxide producers in North America by processing spodumene concentrate produced from assets where we hold an economic interest.
  • Our projects include our Carolina Lithium and Tennessee Lithium projects in the United States and partnerships in Quebec with Sayona Mining (ASX: SYA) and in Ghana with Atlantic Lithium (AIM: ALL; ASX: A11).

ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications

Retrieved on: 
Thursday, February 15, 2024

LOS ANGELES, Feb. 15, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications. Reporting to Founder and CEO Shao-Lee Lin, MD, PhD, Ms. Lee will be responsible for leading investor relations and corporate communications and will join the company’s Senior Leadership Team.

Key Points: 
  • (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications.
  • Reporting to Founder and CEO Shao-Lee Lin, MD, PhD, Ms. Lee will be responsible for leading investor relations and corporate communications and will join the company’s Senior Leadership Team.
  • Ms. Lee began her investor relations career at Life Technologies, which was acquired by Thermo Fisher Scientific in 2014.
  • “I am honored to join ACELYRIN to lead the investor relations and corporate communications functions as we progress on our corporate journey in support of patients,” said Ms. Lee.

Media Alert: BrainChip Demonstrates Human Behavior Detection at IFS Direct Connect 2024

Retrieved on: 
Thursday, February 15, 2024

BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY), the world’s first commercial producer of ultra-low power, fully digital, event-based, neuromorphic AI, will host an exhibit demonstrating human behavior AI at IFS Direct Connect 2024 at the San Jose McEnery Convention Center in San Jose, California, February 21.

Key Points: 
  • BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY), the world’s first commercial producer of ultra-low power, fully digital, event-based, neuromorphic AI, will host an exhibit demonstrating human behavior AI at IFS Direct Connect 2024 at the San Jose McEnery Convention Center in San Jose, California, February 21.
  • BrainChip will spotlight Akida’s neuromorphic advantage, emphasizing the scalability of its IP within Intel’s Open System Foundry.
  • Among the highlights of IFS Direct Connect is a demonstration of NVISO Group AI Human Behavioral Software and BrainChip’s Akida™ neuromorphic compute.
  • “We look forward to showcasing our latest collaborations, IP achievements and AI capabilities to Intel Foundry Services alliance partners, customers, media and analysts joining us at IFS Direct Connect 2024,” said Sean Hehir, CEO of BrainChip.

Renesas to Acquire PCB Design Software Leader Altium to Make Electronics Design Accessible to Broader Market and Accelerate Innovation

Retrieved on: 
Wednesday, February 14, 2024

The current electronics system design flow is a complicated and iterative process that involves multiple stakeholders and design steps, from component selection and evaluation to simulation and PCB physical design.

Key Points: 
  • The current electronics system design flow is a complicated and iterative process that involves multiple stakeholders and design steps, from component selection and evaluation to simulation and PCB physical design.
  • The company has grown into a global market leader with the most popular PCB software tool in use today.
  • With the addition of the world’s first digital platform for design and realization of electronics hardware, Altium 365, Altium’s leading PCB design software creates seamless collaboration across the entire PCB design process.
  • In June 2023, Renesas announced that it had standardized development of all PCB design on the Altium 365 cloud-based platform from Altium.

SSR Mining Provides an Update on Incident at Çöpler

Retrieved on: 
Wednesday, February 14, 2024

SSR Mining Inc. (Nasdaq/TSX: SSRM; ASX: SSR) (“SSR Mining” or the “Company”) provides an update on the incident at Çöpler.

Key Points: 
  • SSR Mining Inc. (Nasdaq/TSX: SSRM; ASX: SSR) (“SSR Mining” or the “Company”) provides an update on the incident at Çöpler.
  • A significant slip occurred at the Çöpler heap leach pad at approximately 6:30am ET on February 13, 2024.
  • The health, safety, and well-being of our employees, contractors, and their families are and continue to be our number one priority.
  • SSR Mining is providing its full cooperation to the regulators on site, and we want to thank them for their assistance.

IperionX Drives Towards Commercial Scale Titanium Metal Production

Retrieved on: 
Wednesday, February 14, 2024

This large-scale titanium furnace is expected to be installed within the Titanium Production Facility during the second quarter, paving the way for the production of titanium metal in mid-2024.

Key Points: 
  • This large-scale titanium furnace is expected to be installed within the Titanium Production Facility during the second quarter, paving the way for the production of titanium metal in mid-2024.
  • A critical IperionX production asset, this large-scale, industrial titanium furnace leverages patented company technologies, such as HAMR1 and HSPT2, to produce sustainable, high-quality and high-strength titanium metal products at commercial scale.
  • In 2023, the IperionX technical team successfully completed two full-scale titanium production test runs that surpassed the core target production parameters for the Titanium Production Facility.
  • Construction Progress - Titanium Production Facility, Virginia
    Construction of the Titanium Production Facility is advancing to schedule, with the HAMR titanium furnace expected to be commissioned and to produce first titanium metal in mid-2024.

Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept

Retrieved on: 
Wednesday, February 14, 2024

MELBOURNE, Australia, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that it has completed enrollment of all patients in the COAST Phase 3 pivotal clinical trial investigating sozinibercept (OPT-302, a vascular endothelial growth factor (VEGF)-C/D inhibitor) in combination with aflibercept, an anti-VEGF-A therapy, for the treatment of wet Age-related Macular Degeneration (wet AMD). The sozinibercept clinical program includes two Phase 3 pivotal trials, COAST and ShORe. Enrollment in ShORe is expected to be completed in calendar Q2 2024. Opthea intends to report topline results from these two trials by mid-2025.

Key Points: 
  • The sozinibercept clinical program includes two Phase 3 pivotal trials, COAST and ShORe.
  • Enrollment in ShORe is expected to be completed in calendar Q2 2024.
  • Opthea intends to report topline results from these two trials by mid-2025.
  • “Completion of patient enrollment in our first pivotal trial marks an important milestone in the development of sozinibercept for the treatment of wet AMD.

OSINT Combine and Seerist Partner to Deliver Comprehensive Threat and Risk Intelligence Solution to Clients

Retrieved on: 
Tuesday, February 13, 2024

SYDNEY, Feb. 13, 2024 /PRNewswire-PRWeb/ -- OSINT Combine, globally recognised as a premier OSINT training and software provider (NexusXplore), is thrilled to announce a new partnership with Seerist Inc., the leading threat and risk intelligence solution for security and intelligence professionals.

Key Points: 
  • Combining OSINT Combine's NexusXplore's advanced search capabilities and Seerist's innovative insight-driven threat and risk intelligence, enables users to get more data and analysis to protect their operations and people better.
  • SYDNEY, Feb. 13, 2024 /PRNewswire-PRWeb/ -- OSINT Combine, globally recognised as a premier OSINT training and software provider (NexusXplore), is thrilled to announce a new partnership with Seerist Inc ., the leading threat and risk intelligence solution for security and intelligence professionals.
  • Seerist compliments this work with its use of AI and impressive network of localised analysts ," said Chris Poulter, Founder and CEO, OSINT Combine.
  • Seerist has been one of the leading providers of AI-driven threat and risk intelligence to governments for the past seven years.